title: The safety and efficacy of 12 versus 24 hours of tirofiban infusion in patients undergoing primary percutaneous coronary intervention.
abstract: OBJECTIVE
  We aimed to investigate the 6-month efficacy and safety of postprocedural 12-hour tirofiban administration versus 24-hour tirofiban administration in patients with ST-segment elevated myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI).
  
  
  METHODS
  This retrospective study enrolled 349 patients with STEMI who underwent primary PCI. Following the administration of bolus tirofiban after primary PCI, those receiving a 12-hour tirofiban infusion as the maintenance dose were classified as group 1 (n = 123) while those receiving a 24-hour infusion were classified as group 2 (n = 226). In-hospital and 6-month major adverse cardiac events were recorded.
  
  
  RESULTS
  There were no statistically significant differences between the 2 groups regarding in-hospital efficacy (in-hospital death: 4.4% vs 5.7%, P = .600 and stent thrombosis 1.8% vs 1.6%, P = .921) and in-hospital safety (2.6% vs 1.6% for major bleeding and 5.3% vs 4.1% for minor bleeding, P = .562). During the 6-month follow-up period, the incidence of the recurrent revascularization (16.1% vs 15.5%, odds ratio [OR] = 1.05 [0.47-3.67]), the repeated nonfatal acute coronary syndrome and/or stent thrombosis (27% vs 24.4%, P = .598, OR = 1.02 [0.42-2.48]), and the cardiovascular deaths (6.6% vs 6.5%, P = .943, OR = 1.03 [0.43-2.43]) were comparable between group 1 and group 2.
  
  
  CONCLUSIONS
  Our study revealed that 12-hour tirofiban administration versus 24-hour tirofiban administration in STEMI who underwent primary PCI was similar with respect to in-hospital efficacy and safety and major adverse cardiac events during 6-month follow-up.
authors.affiliation: Department of Cardiology, Medical School, Ataturk University, Erzurum, Turkey drselimtopcu@yahoo.com.
authors.forename: Selim
authors.initials: S
authors.lastname: Topcu
authors.affiliation: Department of Cardiology, Medical School, Ataturk University, Erzurum, Turkey.
authors.forename: Huseyin
authors.initials: H
authors.lastname: Karal
authors.affiliation: Department of Cardiology, Erzurum Education and Research Hospital, Erzurum, Turkey.
authors.forename: Ahmet
authors.initials: A
authors.lastname: Kaya
authors.affiliation: Department of Cardiology, Medical School, Ataturk University, Erzurum, Turkey.
authors.forename: Eftal Murat
authors.initials: EM
authors.lastname: Bakirci
authors.affiliation: Department of Cardiology, Medical School, Ataturk University, Erzurum, Turkey.
authors.forename: Ibrahim Halil
authors.initials: IH
authors.lastname: Tanboga
authors.affiliation: Department of Cardiology, Erzurum Education and Research Hospital, Erzurum, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Kurt
authors.affiliation: Department of Cardiology, Medical School, Ataturk University, Erzurum, Turkey.
authors.forename: Enbiya
authors.initials: E
authors.lastname: Aksakal
authors.affiliation: Department of Cardiology, Medical School, Ataturk University, Erzurum, Turkey.
authors.forename: Mahmut
authors.initials: M
authors.lastname: Acikel
authors.affiliation: Department of Cardiology, Medical School, Ataturk University, Erzurum, Turkey.
authors.forename: Serdar
authors.initials: S
authors.lastname: Sevimli
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000601:surgery*; D062645:Percutaneous Coronary Intervention; D011182:Postoperative Care / Q000379:methods*; D012189:Retrospective Studies; D013997:Time Factors; D000077466:Tirofiban; D014443:Tyrosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D014443:Tyrosine; D000077466:Tirofiban
keywords: ST-segment elevation myocardial infarction; coronary intervention; primary percutaneous; tirofiban infusion